<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241745</url>
  </required_header>
  <id_info>
    <org_study_id>17-180</org_study_id>
    <nct_id>NCT03241745</nct_id>
  </id_info>
  <brief_title>A Study of Nivolumab in Selected Uterine Cancer Patients</brief_title>
  <official_title>Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of nivolumab and find out what affects, if&#xD;
      any, nivolumab has on people and their risk of gynecologic cancer. The investigators also&#xD;
      want to find out what effects, good or bad, nivolumab has on the patient and their cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase 2 study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>at 24 weeks</time_frame>
    <description>will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Uterine Cancer</condition>
  <condition>Endometrial Carcinoma</condition>
  <condition>Carcinosarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Undifferentiated Sarcoma</condition>
  <condition>High Grade Endometrial Stromal Sarcoma</condition>
  <condition>Clear Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 480 mg IV once every 4 weeks</description>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of metastatic or recurrent uterine cancer&#xD;
             (endometrial carcinoma, carcinosarcoma, clear cell carcinoma, leiomyosarcoma,&#xD;
             undifferentiated sarcoma, high grade endometrial stromal sarcoma) by Memorial Sloan&#xD;
             Kettering Cancer Center. Carcinosarcomas, endometrioid and clear cell carcinomas that&#xD;
             appears to have arisen in the ovary/fallopian tube or peritoneum are also eligible.&#xD;
             Recurrence should not be amenable to curative approaches such as surgical resection or&#xD;
             chemoradiotherapy.&#xD;
&#xD;
          -  Tumor is confirmed to be one of the following: 1. MSI-high, or 2. MMR-deficient, or 3.&#xD;
             Hypermutated defined as ≥20 somatic mutations in the tumor by MSK-IMPACT&#xD;
&#xD;
          -  One or more prior lines of cytotoxic treatment for advanced disease (prior hormonal&#xD;
             therapy is not considered to count as prior lines of therapy)&#xD;
&#xD;
          -  Measurable disease by RECIST 1.1 criteria&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
          -  ECOG Performance status 0-1&#xD;
&#xD;
          -  ECOG Performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 2000/uL, ANC ≥ 1500/uL, PLT ≥ 100,000/uL, HGB ≥ 8 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance of ≥ 40mL/min by Cockroft-Gault&#xD;
             formula&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤ 3 x ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN, except subjects with Gilbert's syndrome who can have&#xD;
             total bilirubin ≤ 3.0 mg/dL&#xD;
&#xD;
          -  Able to sign voluntary written informed consent&#xD;
&#xD;
          -  Female, 18 years of age or older&#xD;
&#xD;
          -  Available archival tumor tissue or patient is willing to undergo new biopsy&#xD;
&#xD;
          -  Premenopausal women of child bearing potential must have a normal urine or serum&#xD;
             beta-HCG prior to enrollment, and must agree to use effective contraception during&#xD;
             treatment with nivolumab and for at least 5 months following the last dose of&#xD;
             nivolumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease eligible for potentially curative treatment with standard chemotherapy,&#xD;
             surgical resection, or chemoradiotherapy.&#xD;
&#xD;
          -  Known or suspected autoimmune disease, except for subjects with vitiligo, diabetes&#xD;
             mellitus, resolved childhood asthma/atopy, residual hypothyroidism due to an&#xD;
             autoimmune immune condition only requiring thyroid hormone replacement, psoriasis not&#xD;
             requiring systemic treatment, or conditions not expected to recur in the absence of an&#xD;
             external trigger.&#xD;
&#xD;
          -  Serious uncontrolled medical disorder or active infection which would impair the&#xD;
             ability of the subject to receive protocol therapy or whose control would be&#xD;
             jeopardized by protocol therapy&#xD;
&#xD;
          -  History of bowel obstruction, refractory ascites, or bowel perforation due to advanced&#xD;
             disease within the past 3 months from start of study treatment.&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4&#xD;
             antibody or any other antibody or drug specifically targeting T cell co-stimulation or&#xD;
             immune checkpoint pathways&#xD;
&#xD;
          -  Patients who have a condition that requires systemic treatment with either&#xD;
             corticosteroids within 7 days of enrollment (systemic corticosteroid therapy is&#xD;
             defined as &gt;10 mg daily prednisone or its equivalent); or who require other&#xD;
             immunosuppressive medications within 14 days of study drug administration. Inhaled or&#xD;
             topical steroids and adrenal replacement doses &gt; 10 mg daily prednisone equivalents&#xD;
             are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
          -  Prior history of malignancy or a concurrent malignancy, with the exception of&#xD;
             cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer,&#xD;
             or in situ carcinoma of the uterine cervix, prostate, or breast, unless a complete&#xD;
             remission was achieved at least 3 years prior to study entry and no additional therapy&#xD;
             is required or anticipated to be required during the study period&#xD;
&#xD;
          -  Breastfeeding women, pregnant women&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical illness&#xD;
&#xD;
               -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C&#xD;
                  virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (if&#xD;
                  patient has documented Hepatitis B and C from within 6 months of enrollment,&#xD;
                  these tests do not need to be repeated.)&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Known allergy or Adverse Drug Reaction to nivolumab, or a history of allergy to study&#xD;
             drug components.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Friedman, MD</last_name>
    <phone>646-888-4247</phone>
    <email>friedmac@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martee Hensley, MD</last_name>
    <phone>646-888-4222</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
    <contact_backup>
      <last_name>Martee Hensley, MD</last_name>
      <phone>646 888-4222</phone>
    </contact_backup>
    <investigator>
      <last_name>Claire Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarie Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surech Nair, MD</last_name>
      <phone>610-402-7880</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>17-180</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Adenomyoepithelioma</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Sarcoma, Endometrial Stromal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

